Vicente Cambra Cambra-Cortés

Dr. Vicente Cambra Cambra-Cortés

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
HCHelena Castañé
Helena Castañé
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
CMCristian Martínez-Navidad
Cristian Martínez-Navidad
CPCristina Placed-Gallego
Cristina Placed-Gallego
VCVicente Cambra Cambra-Cortés
Vicente Cambra Cambra-Cortés
Jorge JovenJorge Joven
Jorge Joven
Paraoxonase-1 (PON1) is an antioxidant enzyme associated with high-density lipoproteins (HDL). Reduced serum PON1 activity is found in diseases marked by oxidative stress and inflammation, but its role in obesity remains unclear. This study investigated PON1 activities and concentrations in morbidly obese individuals and explored the impacts of the genetic polymorphism PON1 rs662 and non-alcoholic fatty liver disease on enzymatic properties. We recruited 1349 morbidly obese patients undergoing bariatric surgery and 823 non-obese volunteers. PON1-related variables, including arylesterase, paraoxonase, and lactonase activities and PON1 concentrations, were examined. Our results showed that morbidly obese individuals exhibited higher PON1 concentrations but lower enzymatic activities than non-obese individuals. We observed inverse associations of arylesterase and paraoxonase activities with waist circumference (rho = −0.24, p < 0.001, and rho = −0.30, p < 0.001, respectively) and body mass index (rho = −0.15, p = 0.001, and rho = −0.23, p < 0.001), as well as direct associations of arylesterase, paraoxonase, and lactonase activities with HDL cholesterol (rho = 0.11, p = 0.005, rho = 0.20, p < 0.001, and rho = 0.20, p < 0.001). No significant differences were observed regarding metabolic syndrome, type 2 diabetes mellitus, hypertension, dyslipidemia, rs662 polymorphism allele frequencies, or the diagnosis of non-alcoholic steatohepatitis. Nevertheless, correlations were found between certain PON1-related variables, steatosis, and ballooning. In conclusion, changes in PON1-related variables in morbidly obese patients are dependent on the disease itself and HDL levels. The relationships between these variables and specific liver histological changes raise intriguing questions for consideration in future studies.

Verified
Journal Article
Open access
PDF file
HCHelena Castañé
Helena Castañé
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
AOAlina Iuliana Onoiu
Alina Iuliana Onoiu
VCVicente Cambra Cambra-Cortés
Vicente Cambra Cambra-Cortés
AHAnna Hernández-Aguilera
Anna Hernández-Aguilera
Jorge JovenJorge Joven
Jorge Joven
We investigated the impact of liver damage on systemic inter-organ communication in an extensive observational case–control study of 923 patients with severe obesity and biopsy-confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) undergoing bariatric surgery. Using a comprehensive panel of circulating organokines, including fibroblast growth factor (FGF) 19, FGF21, adiponectin, galectin-3, irisin, and leptin, along with choline metabolites, we characterized metabolic signaling patterns associated with liver disease severity. Compared to controls, patients with MASLD/MASH exhibited significantly lower levels of FGF19, choline, and trimethylamine, while FGF21, galectin-3, irisin, and leptin were elevated. Sex-specific alterations in leptin and adiponectin were observed in patients with severe obesity but not in controls. Network analysis revealed a complex and individualized interplay among organokines, shaped by age, sex, and anthropometric factors. Despite this complexity, a dysregulation of the FGF21–adiponectin axis was associated with more advanced liver involvement. The large cohort and comprehensive organokine profiling studied provide valuable insights into the role of the FGF21–adiponectin axis on systemic metabolic alterations in severe obesity and their potential clinical implications.

22 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
HCHelena Castañé
Helena Castañé
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
AOAlina Iuliana Onoiu
Alina Iuliana Onoiu
VCVicente Cambra Cambra-Cortés
Vicente Cambra Cambra-Cortés
AHAnna Hernández-Aguilera
Anna Hernández-Aguilera
Jorge JovenJorge Joven
Jorge Joven
We investigated the impact of liver damage on systemic inter-organ communication in an extensive observational case-control study of 923 patients with severe obesity and biopsy-confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) undergoing bariatric surgery. Using a comprehensive panel of circulating organokines, including fibroblast growth factor (FGF) 19, FGF21, adiponectin, galectin-3, irisin, and leptin, along with choline metabolites, we characterized metabolic signaling patterns associated with liver disease severity. Compared to controls, patients with MASLD/MASH exhibited significantly lower levels of FGF19, choline, and trimethylamine, while FGF21, galectin-3, irisin, and leptin were elevated. Sex-specific alterations in leptin and adiponectin were observed in patients with severe obesity but not in controls. Network analysis revealed a complex and individualized interplay among organokines, shaped by age, sex, and anthropometric factors. Despite this complexity, a reproducible dysregulation of the FGF21–adiponectin axis was associated with more advanced liver involvement. The large cohort and comprehensive organokine profiling studied provide valuable insights into the role of the FGF21–adiponectin axis on systemic metabolic alterations in severe obesity and their potential clinical implications.

1 August 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
AOAlina Iuliana Onoiu
Alina Iuliana Onoiu
VCVicente Cambra Cambra-Cortés
Vicente Cambra Cambra-Cortés
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
AHAnna Hernández-Aguilera
Anna Hernández-Aguilera
DPDavid Parada
David Parada
Jorge JovenJorge Joven
Jorge Joven
The effects of long-term adjustments in body weight on the lipid balance in patients with severe obesity are not well understood. This study aimed to evaluate a non-invasive lipidomic approach to identifying biomarkers that could help predict which patients may require additional therapies before and after weight loss. Using mass spectrometry, 275 lipid species were analysed in non-obese controls, patients with severe obesity, and patients one year after bariatric surgery. The results showed that severe obesity disrupts lipid pathways, contributing to lipotoxicity, inflammation, mitochondrial stress, and abnormal lipid metabolism. Although weight loss improved these disturbances, surgery did not fully normalise the lipid profiles of all patients. Outcomes varied depending on their baseline liver health and genetic differences. Persistent alterations in cholesterol handling, membrane composition, and mitochondrial function were observed in partial responders. Elevated levels of sterol lipids, glycerophospholipids, and sphingolipids emerged as markers of complete metabolic recovery, identifying candidates for targeted post-surgical interventions. These findings support the use of lipidomics to personalise obesity treatment and follow-up.

2 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AOAlina Iuliana Onoiu
Alina Iuliana Onoiu
VCVicente Cambra Cambra-Cortés
Vicente Cambra Cambra-Cortés
AJAndrea Jiménez-Franco
Andrea Jiménez-Franco
AHAnna Hernández-Aguilera
Anna Hernández-Aguilera
DPDavid Parada
David Parada
Jorge JovenJorge Joven
Jorge Joven
The effects of long-term adjustments in body weight on lipid balance in patients with severe obesity are not well understood. This study aimed to evaluate a non-invasive lipidomic approach to identify biomarkers that could help predict which patients may require additional therapies before and after weight loss. Using mass spectrometry, 275 lipid species were analysed in non-obese controls, patients with severe obesity, and patients one year after bariatric surgery. The results showed that severe obesity disrupts lipid pathways, contributing to lipotoxicity, inflammation, mitochondrial stress, and abnormal lipid metabolism. Although weight loss improved these disturbances, surgery did not fully normalise lipid profiles in all patients. Outcomes varied depending on baseline liver health and genetic differences. Persistent alterations in cholesterol handling, membrane composition, and mitochondrial function were observed in partial responders. Elevated levels of sterol lipids, glycerophospholipids, and sphingolipids emerged as markers of incomplete metabolic recovery, identifying candidates for targeted post-surgical interventions. These findings support the use of lipidomics to personalise obesity treatment and follow-up.

27 February 2026 in Research Square
Verified
Preprint
Open access
PDF file
AOAlina Iuliana Onoiu
Alina Iuliana Onoiu
LMLara Murray
Lara Murray
YGYlaine Gerardin
Ylaine Gerardin
GSGeetika Singh
Geetika Singh
RERobert Egger
Robert Egger
JJJorge Joven
Jorge Joven
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by steatosis, inflammation, hepatocellular injury, and fibrosis that may progress to cirrhosis or hepatocellular carcinoma. While laparoscopic sleeve gastrectomy (LSG) effectively treats severe obesity and improves liver histology, traditional pathological assessments rely on subjective evaluations. This study aimed to objectively assess LSG impact on MASH histological outcomes using digital pathology. We conducted a retrospective study analyzing paired liver biopsies from 44 patients who required a second bariatric intervention due to suboptimal outcomes following initial LSG. Wedge biopsies were obtained during both surgical procedures using standardized techniques, allowing comparisons between specimens obtained at the initial intervention and post-LSG. The liver tissue sections were digitized and analyzed using LiverExplore, an artificial intelligence (AI)-powered digital pathology tool to quantify hepatic cellular features, tissue architecture, and collagen characteristics. LSG resulted in significant improvements in key histopathological parameters, including reduced hepatic steatosis (p = 7.2×10⁻ 9 ) and hepatocellular ballooning (p = 2.6×10⁻⁴). While overall fibrosis scores remained unchanged, distinct fibrotic subtypes demonstrated marked improvement, with significant reductions in periportal fibrosis (p = 2.2×10⁻ 4 ), incomplete septal fibrosis (p = 6.9×10⁻⁶), and complete septal fibrosis (p = 6.6×10⁻⁴). The hepatic immune landscape showed comprehensive reorganization with increased neutrophil (p = 6.4×10⁻⁵) and eosinophil (p = 5.3×10⁻⁴) infiltration, alongside zonal redistribution of immune cells throughout the liver parenchyma. AI-enhanced digital pathology enables objective assessment of hepatic changes post-bariatric surgery. LSG improved key MASH features. Post-surgical increase in neutrophils and eosinophils along with zonal immune reorganization suggests immune-mediated tissue remodeling contributing to recovery. These findings support LSG efficacy for MASH treatment and demonstrate AI utility in capturing complex pathological changes.